AstraZeneca is recruiting patients for a PHASE3 clinical trial testing nivolumab plus ipilimumab for mesothelioma.
The trial, designated NCT06097728, aims to enroll up to 825 participants at 178 sites, including locations in Arizona, California, Colorado.
About the Study
This is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of Volrustomig (MEDI5752) + Carboplatin + Pemetrexed vs the investigator’s choice of platinum + Pemetrexed or Nivolumab + Ipilimumab in participants with unresectable pleural mesothelioma.
Treatment Approach
This trial uses a combination of checkpoint inhibitors that was FDA-approved for mesothelioma in 2020.
Key trial details:
- Phase: PHASE3
- Sponsor: AstraZeneca
- Enrollment target: 825
- Status: RECRUITING
Why This Trial Matters
Phase 3 trials are the final stage before FDA approval, making this study particularly significant for patients seeking access to new treatments.
Study Locations
The trial is recruiting at:
- Research Site, Arizona
- Research Site, California
- Research Site, California
- Research Site, Colorado
- Research Site, Florida
How to Enroll
Patients interested in this trial should:
- Discuss eligibility with their oncologist
- Review the full eligibility criteria on ClinicalTrials.gov
- Contact the study coordinator for screening